Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
| Revenue (TTM) | $65.77B |
| Gross Profit (TTM) | $50.46B |
| EBITDA | $29.52B |
| Operating Margin | 38.60% |
| Return on Equity | 18.90% |
| Return on Assets | 12.60% |
| Revenue/Share (TTM) | $26.42 |
| Book Value | $18.58 |
| Price-to-Book | 7.04 |
| Price-to-Sales (TTM) | 4.96 |
| EV/Revenue | 5.57 |
| EV/EBITDA | 18.88 |
| Quarterly Earnings Growth (YoY) | -19.30% |
| Quarterly Revenue Growth (YoY) | 4.90% |
| Shares Outstanding | $2.47B |
| Float | $2.47B |
| % Insiders | 0.06% |
| % Institutions | 82.24% |
Volatility is currently contracting
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck said on Friday it signed seven voluntary licensing agreements with generic drug manufacturers to make and sell lower-cost versions of its experimental once-monthly oral HIV pill in 129 low- and lower-middle-income countries.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally.
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.
Many think the next standard cancer treatment will pair two innovations.
Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing further LDL-C reduction, with peak sales potential estimated at $5 billion by 2034, strengthening MRK's cardiometabolic portfolio.
Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRK and any ticker you trade — then tracks every position and per-strategy win rate.
